Hims & Hers Health (HIMS) shares were down more than 3.5% in Friday's premarket activity after closing down 7.7% on Thursday following a US Food and Drug Administration determination that a shortage of Eli Lilly's (LLY) popular weight loss drug tirzepatide has ended.
Hims & Hers Health was allowed to produce its version of the drug as long as the FDA determined there was a shortage.
The FDA said in a letter on Thursday that "the tirzepatide injection product shortage is resolved."
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。